Evidence map›Paper›PMID 36497219›Full record

ReviewCancers2022

Nanoplasmonics Enabling Cancer Diagnostics and Therapy.

Ren A Odion, Yang Liu, Tuan Vo-Dinh

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ren A OdionFitzpatrick Institute for Photonics, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-8290-3865
Yang LiuFitzpatrick Institute for Photonics, Duke University, Durham, NC 27708, USA.
Tuan Vo-DinhFitzpatrick Institute for Photonics, Duke University, Durham, NC 27708, USA.
Duke University · US

Funding

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancerR01EB028078 · NIBIB · DUKE UNIVERSITY · PI VO-DINH, TUAN · 2019 to 2022
$2.1M
NIBIB NIH HHS R01 EB028078NIH HHS R01EB028078-01A1
6 · The paper itself

Abstract

In this paper, we highlight several advances our laboratory has developed in the pursuit of cancer diagnostics and therapeutics by integrating plasmonics, photonics, and nanotechnology. We discuss the development and applications of plasmonics-active gold nanostar (GNS), a uniquely shaped nanoparticle with numerous branches that serve to greatly amplify the thermal generation at resonant wavelengths. GNS has also been successfully used in tumor imaging contexts from two-photon fluorescence to surface-enhanced Raman scattering (SERS) sensing and imaging. Finally, GNS has been coupled with immunotherapy applications to serve as an effective adjuvant to immune checkpoint inhibitors. This combination of GNS and immunotherapy, the so called synergistic immuno photo nanotherapy (SYMPHONY), has been shown to be effective at controlling long-lasting cancer immunity and metastatic tumors.

Indexed as

gold nanostarimmunotherapyphotothermalplasmonics

Identifiers

PMID36497219
PMCPMC9739286
OpenAlexW4309722661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.